

Dear Editors,

we have carefully considered the reviewers' comments and the answers to the issues raised in the peer-review report are below:

1. A table describing the quoted cardiovascular outcome trials is provided (see Table 1 in the Main document).
2. A figure depicting the most plausible and accepted mechanisms of SGLT2 inhibitors in heart failure is provided (see Figure 1 in the Main document).
3. Ongoing heart failure outcome studies addressing existing evidence gaps across a range of ejection fraction values and clinical status are provided (see Table 2 in the Main document).
4. Recent guidelines of the American Diabetes Association (Standards of medical care in diabetes – 2020) that include this drugs in the recommendations for heart failure patients is reported within the Main text in the Introduction section („American Diabetes Association has already recommended new strategies in the treatment of diabetic patients with established atherosclerotic cardiovascular disease and patients with heart failure, and that is the preferential use of SGLT2 inhibitors (empa-, dapa- and canagliflozin) in these patients.”).

We hope that the answers are acceptable.

Kind regards,

Petra Grubić Rotkvić, MD (corresponding author)